Should NOAC monotherapy replace aspirin as the preferred antithrombotic strategy after TAVI, particularly in younger patients where valve durability is a priority? ##Reference## Dodgson CS, Herstad J, Kløve SF, et al. Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial. JAMA.

2026.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including content from our industry partners. We do not associate with the views of any individual, community, organization, industry partner, or political party.…